Journal Mobile Options
Table of Contents
Vol. 38, No. 1, 2001
Issue release date: January–February 2001
Section title: Research Paper
J Vasc Res 2001;38:39–46
(DOI:10.1159/000051028)

Nitric Oxide, Peroxynitrite and cGMP in Atherosclerosis-Induced Hypertension in Rabbits: Beneficial Effects of Cicletanine

Szilvássy Z.a · Csont T.b · Páli T.c · Droy-Lefaix M.-T.d · Ferdinandy P.b
aDepartment of Pharmacology, University of Debrecen, Debrecen, bCardiovascular Research Group, Department of Biochemistry, University of Szeged, cDepartment of Biophysics, Biological Research Center, Szeged, Hungary, and dIPSEN-Beaufour, Paris, France
email Corresponding Author

Abstract

We studied the effect of the furopyridine derivative antihypertensive drug, cicletanine, on blood pressure, vascular nitric oxide (NO) and cyclic guanosine 3′:5′-monophosphate (cGMP) content in the aorta and the renal and carotid arteries, aortic superoxide production, and serum nitrotyrosine level in hypertensive/atherosclerotic rabbits. The effect of cicletanine was compared to that of furosemide. Rabbits were fed a normal or a cholesterol-enriched (1.5%) diet over 8 weeks. On the 8th week, the rabbits were treated per os with 2 × 50 mg/kg daily doses of cicletanine, furosemide, or vehicle for 5 days (n = 5–6 in each groups). The cholesterol diet increased mean arterial blood pressure (MABP) from 86 ± 1 to 94 ± 2 mm Hg (p < 0.05). Cicletanine decreased MABP in atherosclerotic rabbits to 85 ± 1 mm Hg (p < 0.05), but it did not affect MABP in normal animals. Furosemide was without effect in both groups. In normal animals, NO content (assessed by electron spin resonance after in vivo spin trapping) in the aorta and the renal and carotid arteries was increased by cicletanine, and the drug increased cGMP in the renal artery as measured by radioimmunoassay. The cholesterol-enriched diet decreased both vascular NO and cGMP and increased aortic superoxide production assessed by lucigenin-enhanced chemiluminescence and serum nitrotyrosine determined by ELISA. In atherosclerotic animals, cicletanine increased NO and cGMP content in the aorta and the renal and carotid arteries and decreased aortic superoxide production and serum nitrotyrosine. Furosemide did not influence these parameters. We conclude that cicletanine lowers blood pressure in hypertensive/atherosclerotic rabbits. The antihypertensive effect of the drug in atherosclerosis may be based on its beneficial effects on the vascular NO-cGMP system and on the formation of reactive oxygen species.

© 2001 S. Karger AG, Basel


  

Key Words

  • Nitric oxide
  • cGMP
  • Peroxynitrite
  • Cicletanine
  • Furosemide
  • Atherosclerosis
  • Cholesterol diet

 introduction

The furopyridine-derivative cicletanine is an antihypertensive drug with a vasorelaxant effect in addition to its diuretic property [1, 2]. The mechanism by which cicletanine decreases vascular tone is not clearly understood. The drug has been shown to inhibit low-Km Ca2+-calmodulin-dependent cyclic guanosine 3′:5′-monophosphate (cGMP) phosphodiesterase (PDE) and cGMP-selective PDE [3, 4] and to increase cGMP content of the heart [5]. Inhibition of cGMP-PDE has been proposed to serve as an important mechanism of vasorelaxation promoted by cicletanine. cGMP was shown to modulate several potassium channels [6, 7]. Accordingly, cicletanine has also been shown to stimulate K+ efflux in human red blood cells [8] and to open ATP-sensitive K+ channels in human epigastric artery rings [9] and in isolated working rat hearts [10]. Nitric oxide (NO) regulates potassium channels through both cGMP-dependent and independent pathways [7, 11] [for a review; see ref. 12], which suggests that the NO-cGMP-potassium channel pathway plays an important role in the regulation of vascular tone. The vascular effect of cicletanine was previously shown to involve endothelium-dependent vasodilation [13]. We have recently shown that cicletanine increases vascular NO content in isolated rabbit aortic rings [14], which suggests that NO is involved in the antihypertensive effect of the drug.

Atherosclerosis is a well-known ‘NO-deficient state’ in the vasculature, which leads to sustained arterial hypertension [for reviews, see ref. 15, 16] and reduced cardiovascular tolerance to stress [for a review, see ref. 17]. Increasing evidence has accumulated in recent years showing that a high-cholesterol diet impairs NO-cGMP signaling in both endothelial and nonendothelial cells [18, 19, 20, 21], possibly due to enhanced formation of peroxynitrite, a reaction product of NO and superoxide [22, 23]. Therefore, antihypertensive drugs which restore normal NO-cGMP signaling in the vasculature might be especially advantageous in hypertension primarily induced by atherosclerosis/hyperlipidemia [for reviews, see ref. 24, 25].

In the present study we examined the effects of cicletanine on blood pressure and vascular NO and cGMP contents in the aorta and the renal and carotid arteries, superoxide production in the aorta, and serum nitrotyrosine level, a marker for peroxynitrite formation, in normotensive and in experimental atherosclerosis-induced hypertension in rabbits. The effect of cicletanine was compared to that of the structurally similar diuretic drug, furosemide. Here we show that cicletanine lowers blood pressure and increases vascular NO and cGMP content and attenuates the formation of superoxide and peroxynitrite in atherosclerotic rabbits.

 

 methods

The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85–23, revised 1985).

 animals and treatments

The experiments were carried out with adult, male New Zealand white rabbits (3.0–3.5 kg) housed as described [26] and fed either standard laboratory chow or chow enriched with 1.5% cholesterol over a period of 8 weeks, which leads to the development of hyperlipidemia, atherosclerosis, and hypertension as described earlier [27, 28]. On the last week of the diet period, the animals were treated orally with 2 × 50 mg/kg daily doses of either cicletanine, furosemide, or their vehicle for 5 days (n = 5–6 in each group). A polyethylene cannula connected to a pressure transducer (B. Braun-Melsungen, Melsungen, Germany) was introduced into the distal third of the central ear artery for recording mean arterial blood pressure (MABP) in the conscious animals [26]. Thereafter, blood samples were taken for the assay of serum lipids and nitrotyrosine. The animals were then sacrificed and vessel samples were taken for cGMP and superoxide assays. Vascular NO was measured in separate experiments (n = 5 in each group). Vascular NO and cGMP contents were studied in the thoracic aorta and the carotid and renal arteries. We have decided to study these vessels since they are important in the development of human hypertension induced by atherosclerosis. Superoxide production was studied in the aorta.

 determination of serum cholesterol level

Serum cholesterol level was determined from blood samples taken prior to and after ingestion of cholesterol-enriched diet for 7 or 8 weeks. The samples were assayed by means of an automatic analyzer (Beckman Model 700, Chemistry System, Miami, Fla., USA) using Boehringer cholesterol kits (Ingelheim, Germany) as described [27].

 measurement of vascular no

Vascular NO content was determined in separate experiments (n = 5 in each group) by electron spin resonance (ESR) after in vivo spin trapping as described previously [29, 30, 31]. The spin-trap diethyldithio-carbamate (DETC, 200 mg/kg), 50 mg/kg FeSO4 and 200 mg/kg sodium citrate were slowly administered intravenously into an ear vein under ether anesthesia. DETC was dissolved in distilled water and was injected separately from FeSO4 and sodium citrate in a 0.5-ml volume to avoid precipitation of Fe2+-(DETC)3. FeSO4 and sodium citrate were dissolved in distilled water and the pH was set to 7.4 with NaOH and the volume of the solution was brought to 1 ml before injection. Five minutes after DETC and FeSO4/citrate treatment (i.e. after 5 min of in vivo spin trapping), the animals were sacrificed and the vessels were instantly isolated and washed for 30 s in oxygenated Krebs buffer (37°C, pH = 7.4) to eliminate blood. Tissue samples (100 mg) were transferred into quartz tubes and frozen in liquid nitrogen until assayed for the specific spectra of the NO-Fe2+-(DETC)2 complex. ESR spectra were recorded with a Bruker ECS106 spectrometer (Rheinstetten, Germany) operating at X band with 100 kHz of modulation frequency at a temperature of 160 K using 10 mW microwave power to avoid saturation. Scans were traced with 2.85 G modulation amplitude, 340 G sweep width, and 3356 G central field as described [21]. After subtraction of the background signal, analysis of the NO signal intensity was performed with double integration, and NO content was expressed in arbitrary units. The detection limit of NO by this highly selective ESR method is approximately 0.05 nmol/g wet tissue weight [32].

 vascular cgmp content

Tissue cGMP content was determined in separate experiments as described [26, 30]. In brief, the vessel samples were instantly frozen and pulverized in liquid nitrogen at the end of the drug treatments. The samples were then homogenized in 10 vol of 6% (v/v) trichloroacetic acid in a mortar cooled to –70°C. After thawing, the samples were centrifuged at 15,000 g for 10 min at 4°C. Supernatant was extracted with 5 ml water- saturated ether over 5 min. The ether fraction was discarded and the extraction was then repeated five times. Samples were then evaporated under nitrogen and assayed for cGMP content using Amersham radioimmunoassay kits. Values were expressed as pmol/mg wet tissue weight.

 measurement of vascular superoxide production

Superoxide production in fresh aortic rings was assessed by lucigenin-enhanced chemiluminescence [33]. Aortic rings (approximately 150 mg) were placed in 1 ml air-equilibrated Krebs-Henseleit solution containing 10 mmol/l HEPES-NaOH (pH 7.4) and 0.25 mmol/l lucigenin. Chemiluminescence was measured at room temperature in a liquid scintillation counter using a single active photomultiplier positioned in out-of-coincidence mode.

 determination of serum nitrotyrosine

The concentration of free nitrotyrosine in serum samples, a marker for peroxynitrite generation [34], was assayed by ELISA. ELISA was conducted as described by us [35] and the supplier (Cayman Chemical, Ann Arbor, Mich., USA). Briefly, 210-μl serum samples were added to 4× volume 4°C ethanol, vortexed and spinned at 3,000 g for 10 min. Supernatant was evaporated under nitrogen and redissolved in 105 μl ultra-pure water. Samples were then incubated overnight with antinitrotyrosine rabbit IgG and nitrotyrosine acetylcholinesterase tracer in precoated (mouse anti-rabbit IgG) microplates followed by development with Ellman’s reagent for 60 min. Serum nitrotyrosine concentration is expressed as nmol/l.

 assessment of direct peroxynitrite scavenging effect of cicletanine and furosemide in vitro

The reaction of peroxynitrite with tyrosine induces nitration of its aromatic ring via intermediate formation of tyrosyl radicals, thereby yielding nitrotyrosine and dityrosine [34]. It has been previously shown that addition of peroxynitrite to Krebs-Henseleit buffer containing 0.3 mML-tyrosine and 95% O2/5% CO2 at 37°C (pH 7.4) results in rapid (<1 min) formation of dityrosine which can be detected by both fluorescence spectroscopy and high-performance liquid chromatography (HPLC) with an excellent linear correlation (r2 = 0.98) between the HPLC and fluorescence-based determinations of dityrosine in the same sample [36, 37].

Reactions were performed in Krebs-Henseleit buffer containing 0.3 mML-tyrosine and 95% O2/5% CO2 at 37°C (pH 7.4). Stock solutions (100 μl) of cicletanine, furosemide, and urate (a well-known peroxynitrite scavenger which served as positive control [38, 39]) were added to microcentrifuge tubes to give a final concentration in 1,800 μl of 0 (vehicle), 30, 100, 300, or 1,000 μM, respectively. An aliquot of the buffer (1,700 μl) was then added to each tube. The tubes were immediately capped, vortexed, and placed into a 37°C waterbath for 2 min. Each tube was briefly opened and peroxynitrite (30 μl; peroxynitrite was prepared as described [37]) was added to give a final concentration of 3 or 30 μM, and then the tube was recapped. Tubes were immediately vortexed for 15 s, incubated for 10 min at 37°C, and then placed on ice. The entire volume of the reaction mixture was transferred into a plastic cuvette for fluorometric assay. In order to detect dityrosine, samples were excited at a wavelength of 320 nm and scanned between the emission wavelengths of 360 and 500 nm (scan time: 3 s) in a spectrofluorometer (Shimadzu, Model RF 5000).

The fluorescent signal amplitude was measured at 411.2 nm and any background fluorescent signal derived from Krebs-Henseleit buffer containing L-tyrosine was subtracted from this. Inhibition of dityrosine formation by a test compound was calculated as the percentage of the peak amplitude compared to that in the presence of the vehicle.

 statistical analysis

Data presented as means ± standard error (SEM) were analyzed by one-way analysis of variance (ANOVA). If a difference was established, a modified t test according to Bonferroni was applied between groups.

 

 results


 serum cholesterol level

After 7 and 8 weeks of the cholesterol-enriched diet, serum total cholesterol increased from the pre-diet value of 1.6 ± 0.3 to 22.9 ± 3.1 and 21.8 ± 2.2 mmol/l in animals treated with the vehicle for cicletanine. Neither cicletanine nor furosemide influenced the diet-induced increase in serum cholesterol level and neither of them produced any effect on serum cholesterol level in time-matched controls.

 mean arterial blood pressure

Exposure to a cholesterol-enriched diet over 8 weeks significantly increased MABP in conscious rabbits (fig. 1). MABP did not change in the time-matched control group. Neither cicletanine nor furosemide influenced MABP in normal animals. In atherosclerotic animals, cicletanine significantly decreased MABP, whereas furosemide was without effect.

FIG01

Fig. 1. Effect of cicletanine and furosemide on mean arterial blood pressure in normal and atherosclerotic rabbits. Results are means ± SEM, n = 6 in each group. * p < 0.05 atherosclerotic vs. normal; # p < 0.05 cicletanine vs. vehicle.

 vascular no content

While a basal NO signal was detected in vessels from normal animals, NO was nondetectable in cholesterol-fed rabbits (table 1). In normal animals, cicletanine produced a significant increase in vascular NO content in all samples studied. Cicletanine-induced NO accumulation was the most pronounced in the renal artery. In atherosclerotic animals, cicletanine attenuated the decrease in NO content in all the three different vessels studied, however, NO levels remained significantly lower than that in normal animals. Cicletanine-induced increase in vascular NO level was the most significant in the renal artery. Furosemide did not change vascular NO signal.

TAB01

Table 1. Effect of cicletanine and furosemide on vascular NO signal intensity and cGMP content in the aorta and the carotid and renal arteries of normal and atherosclerotic rabbits

 vascular cgmp content

In normal rabbits, cicletanine significantly increased vascular cGMP concentration in the renal artery, whereas it did not significantly influence cGMP content in the aorta and the carotid artery (table 1). cGMP content was significantly decreased by the 8-week cholesterol-enriched diet in samples from either the renal and carotid arteries or the aorta. In atherosclerotic rabbits, cicletanine significantly attenuated the decrease in cGMP level in all the vascular tissues studied. Furosemide did not change vascular cGMP in normal or atherosclerotic rabbits.

 aortic superoxide production

Superoxide production assessed by lucigenin-enhanced chemiluminescence was markedly enhanced in aortic rings obtained from cholesterol-fed rabbits. Cicletanine significantly reduced superoxide production while furosemide had no effect (fig. 2).

FIG02

Fig. 2. Lucigenin-enhanced chemiluminescence in aortic rings obtained from normal and atherosclerotic rabbits. Results are means ± SEM, n = 5–6 in each group. * p < 0.05 atherosclerotic vs. normal.

 serum nitrotyrosine

High-cholesterol diet increased serum free nitrotyrosine content when compared to controls. Cicletanine decreased nitrotyrosine level in hypercholesterolemic rabbits while it did not significantly decrease this parameter in normal animals. Furosemide remained ineffective in both normal and hyperlipidemic rabbits (fig. 3).

FIG03

Fig. 3. Serum nitrotyrosine concentration in normal and atherosclerotic rabbits. Results are means ± SEM, n = 6 in each group. * p < 0.05 atherosclerotic vs. normal.

 inhibition of peroxynitrite-induced dityrosine formation in vitro

When 3 μM (fig. 4) or 30 μM (data not shown) peroxynitrite was added to Krebs-Henseleit buffer containing 0.3 mML-tyrosine at physiological pH and temperature, neither cicletanine, nor furosemide inhibited peroxynitrite-induced dityrosine formation, however, it was concentration-dependently inhibited by the peroxynitrite scavenger urate, which served as positive control for these in vitro studies (fig. 4).

FIG04

Fig. 4. Inhibitory effects of cicletanine, furosemide and the positive control urate on dityrosine formation induced by 3 μM peroxynitrite in Krebs-Henseleit buffer containing bicarbonate/CO2 and L-tyrosine at physiological temperature and pH. Results are means ± SEM, n ≥3.

 

 discussion

The results show that cicletanine lowers MABP in conscious rabbits with experimental hypercholesterolemia/atherosclerosis without affecting normal blood pressure in healthy, normotensive conscious rabbits. The antihypertensive effect of cicletanine in atherosclerotic rabbits is accompanied with an increase in vascular NO and cGMP content and a decrease in vascular superoxide production and in serum nitrotyrosine level, a marker for peroxynitrite production. Furosemide, a diuretic drug which is structurally similar to cicletanine, did not affect blood pressure and vascular NO and cGMP contents, superoxide production, and serum nitrotyrosine in control or hypertensive rabbits. This suggests that the antihypertensive effect of cicletanine is not related to its diuretic effect, however, the drug improves the disturbed NO-cGMP signaling in atherosclerosis, thereby normalizing blood pressure in atherosclerotic/hypertensive animals.

It has been previously shown that cicletanine does not significantly affect normal blood pressure [40, 41, 42], however, its antihypertensive effect is well documented in spontaneously hypertensive rats and hypoxia-induced pulmonary hypertension [43, 44]. The drug also reverses vascular hyperactivity due to sympathetic overactivity [43] and pregnancy [9]. Similarly to these results, cicletanine influenced blood pressure only in hypertensive but not in normotensive rabbits. This is the first demonstration that cicletanine is able to reduce blood pressure in hyperlipidemic/atherosclerotic animals.

Our present results showed that although the drug increased vascular NO level by approximately 100% in the aorta and the carotid and renal arteries, it increased vascular cGMP level significantly (approximately 50%) only in the renal artery in normal animals. Cicletanine produced a moderate decrease in aortic superoxide production and serum nitrotyrosine level which may explain the indirect elevation of vascular NO levels. These findings may show that activation of the normal NO-cGMP system does not lead to a hypotensive effect, possibly due to the normal function of other local regulatory mechanisms of the vascular tone in healthy normotensive rabbits.

Atherosclerosis is a well known ‘NO-deficient state’ in the vasculature which, among other factors, leads to hypertension [15, 16]. Numerous studies have demonstrated that a dysfunction in the release of EDRF/NO occurs already at an early stage of the development of atherosclerosis in animals and humans [45, 46]. A high-cholesterol diet impairs NO-cGMP signaling in both endothelial and non-endothelial cells [18, 19, 20, 21]. It has been shown that hypercholesterolemia leads to enhanced superoxide production in the vasculature [23, 47, 48]. This suggests increased formation of peroxynitrite in hyperlipidemia/atherosclerosis [22, 23, 49]. Accordingly, we have shown here that hyperlipidemia/atherosclerosis decreased vascular NO content to a level nondetectable by ESR and decreased cGMP by approximately 60% in the aorta and the carotid and renal arteries, vascular beds which have a high impact on the development of atherosclerosis-induced hypertension. We have also shown that both aortic superoxide formation and serum peroxynitrite concentration increased in cholesterol-fed rabbits. To the best of our knowledge, this is the first demonstration that serum free nitrotyrosine level, a marker for peroxynitrite formation, increases in hyperlipidemic/atherosclerotic animals.

Cicletanine restored NO and cGMP levels close to their normal level, decreased superoxide production and serum nitrotyrosine concentration, and lowered blood pressure in atherosclerotic rabbits. This suggests that restoration of impaired NO-cGMP signaling and a decreased in the formation of superoxide and peroxynitrite leads to normalization of blood pressure in atherosclerotic animals.

The mechanism by which cicletanine increases the ratio of NO and superoxide, thereby decreasing peroxynitrite formation and increasing cGMP level, is not precisely known. Our in vitro studies show that cicletanine does not directly scavenge peroxynitrite. Therefore, stimulation of NO synthase, inhibition of superoxide formation, or enhancement of detoxification mechanisms against peroxynitrite might play a role [22, 50, 51]. It should be noted that cicletanine may also increase the vascular cGMP level via its well-defined cGMP phosphodiesterase inhibitory effect as well as through increasing vascular NO content.

The diuretic drug furosemide failed to modify vascular NO, cGMP, superoxide, or serum nitrotyrosine and failed to decrease blood pressure in atherosclerotic animals. Since the hypertension model used in the present study [27, 28] is not characterized by volume expansion or sodium retention, the ineffectiveness of diuretics on blood pressure is not surprising. This also suggests that the antihypertensive effect of cicletanine is based on its possible direct vascular effects detailed above rather than its diuretic property in atherosclerotic conscious rabbits.

In summary, atherosclerosis induced by a high cholesterol diet leads to a decrease in vascular NO and cGMP content and an increase in superoxide and peroxynitrite production which results in the development of hypertension. Cicletanine increases vascular NO and cGMP content, decreases superoxide and peroxynitrite formation and lowers blood pressure in hypertensive/atherosclerotic conscious rabbits. This suggests that cicletanine might be advantageous in the treatment of hypertension induced by the disturbed NO-cGMP pathway due to atherosclerosis.

 

 acknowledgments

This work was supported by grants from IPSEN-Beaufour, Paris, France; Hungarian Scientific Research Found (T029843), Hungarian Ministries of Education (FKFP-0340/2000 and FKFP-0485/2000) and Health (ETT 51/2000), and Hungarian Space Research Office, Budapest, Hungary.


References

  1. Chabrier PE, Guinot P, Tarrade T, et al: Cicletanine; in Scriabine A (ed): Cardiovascular Drug Reviews. New York, Raven Press, 1988;166–179.
  2. Bukowski RD, Wagman P, De Wan P, Xue H: Vascular actions of cicletanine. Arch Mal Coeur 1989;82:45–50.
  3. Silver PJ, O’Connor B, Cumiskey WR, Van Aller G, Hamel LT, Bentley RG, Pagani ED: Inhibition of low-Km cGMP phosphodiesterases and Ca++-regulated protein kinases and relationship to vasorelaxation by cicletanine. J Pharmacol Exp Ther 1991;257:382–391.

    External Resources

  4. Silver PJ, Buchholz A, Dundore RL, Harris AL, Pagani ED: Inhibition of low Km cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine. J Cardiovasc Pharmacol 1990;16:501–505.
  5. Szilvassy Z, Jakab I, Bor P, Koltai M, Tarrade T, Esanu A, Braquet PG, Lonovics J: Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: Possible role of cardiac cyclic nucleotides. Coronary Artery Dis 1993;4:443–452.
  6. Sakuta H, Okamoto K, Tandai M: Atrial natriuretic factor potentiates glibenclamide-sensitive K+ currents via activation of receptor guanylate cyclase in follicle-enclosed Xenopus oocytes. Eur J Pharmacol 1994;267:281–287.
  7. Yao XQ, Segal AS, Welling P, Zhang XQ, McNicholas CM, Engel D, Boulpaep EL, Desir GV: Primary structure and functional expression of a cGMP-gated potassium channel. Proc Natl Acad Sci USA 1995;92:11711–11715.

    External Resources

  8. Garay RP, Nazaret C, Diez J, Etienne A, Bourgain R, Braquet P: Stimulation of K+ fluxes by diuretic drugs in human red cells. Biochem Pharmacol 1984;33:2013–2020.
  9. Ebeigbe AB, Cabanie M: In vitro vascular effects of cicletanine in pregnancy-induced hypertension. Br J Pharmacol 1991;103:1992–1996.
  10. Ferdinandy P, Szilvassy Z, Droy-Lefaix MT, Tarrade T, Koltai M: KATP channel modulation in working rat hearts with coronary occlusion: Effects of cromakalim, cicletanine, and glibenclamide. Cardiovasc Res 1995;30:781–787.
  11. Najibi S, Cowan CL, Palacino JJ, Cohen RA: Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol 1994;266:H2061–H2067.

    External Resources

  12. Faraci FM, Heistad DD: Regulation of the cerebral circulation: Role of endothelium and potassium channels. Physiol Rev 1998;78:53–97.
  13. Bukoswki RD, Bo J, Xue H, Bian K: Antiproliferative and endothelium-dependent vasodilator properties of 1,3-dihydro-3-p-chlorophenyl-7-hydroxy-6-methyl-furo-(3,4c)pyridine hydrochloride (cicletanine). J Pharmacol Exp Ther 1993;265:30–35.
  14. Ferdinandy P, Szilvassy Z, Garay RP, Droy-Lefaix M-T: Interaction between vascular nitrate tolerance and cGMP phosphodiesterase inhibitors, cicletanine and zaprinast (abstract). J Mol Cell Cardiol 1999;30:A118.
  15. Dusting GJ: Nitric oxide in cardiovascular disorders. J Vasc Res 1995;32:143–161.
  16. Quyyumi AA: Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am J Med 1998;105:32S–39S.

    External Resources

  17. Ferdinandy P, Szilvassy Z, Baxter GF: Adaptation to myocardial stress in disease states: Is preconditioning a healthy heart phenomenon? Trends Pharmacol Sci 1998;19:223–229.
  18. Simonet S, Porro de Bailliencourt J, Descombes JJ, Mennecier P, Laubie M, Verbeuren TJ: Hypoxia causes an abnormal contractile response in the atherosclerotic rabbit aorta. Implication of reduced nitric oxide and cGMP production. Circ Res 1993;72:616–630.
  19. Lefer AM, Ma X: Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arteriosc Thromb 1993;13:771–776.
  20. Deliconstatinos G, Villioyou V, Stavrides JC: Modulation of particulate nitric oxide synthase activity and peroxynitrite synthesis in cholesterol enriched endothelial cell membranes. Biochem Pharmacol 1995;49:1589–1600.
  21. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E, Szentgyörgyi R, Nagy I, Koltai M, Dux L: Loss of pacing-induced preconditioning in rat hearts: Role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol 1997;29:3321–3333.
  22. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA, Tarpey MM: Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044–1048.
  23. Kojda G, Harrison D: Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999;43:562–571.
  24. McHugh J, Cheek DJ: Nitric oxide and regulation of vascular tone: Pharmacological and physiological considerations. Am J Crit Care 1998;7:131–140.
  25. Luscher TF, Noll G: Endothelial function as an end-point in interventional trials: Concepts, methods and current data. J Hypertens 1996;14:S111–S119.
  26. Szilvassy Z, Ferdinandy P, Bor P, Jakab I, Lonovics J, Koltai M: Ventricular overdrive pacing-induced anti-ischemic effect: A conscious rabbit model of preconditioning. Am J Physiol 1994;266:H2033–H2041.

    External Resources

  27. Szilvassy Z, Ferdinandy P, Szilvassy J, Nagy I, Karcsu S, Lonovics J, Dux L, Koltai M: The loss of pacing-induced preconditioning in atherosclerotic rabbits: Role of hypercholesterolemia. J Mol Cell Cardiol 1995;27:2559–2569.
  28. Szilvassy Z, Ferdinandy P, Cluff CW, Elliott GT: Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis. J Cardiovasc Pharmacol 1998;32:206–212.
  29. Ferdinandy P, Csont T, Csonka C, Torok M, Dux M, Nemeth J, Horvath LI, Dux L, Szilvassy Z, Jancso G: Capsaicin-sensitive local sensory innervation is involved in pacing-induced preconditioning in rat hearts: Role of nitric oxide and CGRP? Naunyn Schmiedebergs Arch Pharmacol 1997;356:356–363.
  30. Csont T, Pali T, Szilvassy Z, Ferdinandy P: Lack of correlation between myocardial nitric oxide and cyclic guanosine monophosphate content in both nitrate-tolerant and nontolerant rats. Biochem Pharmacol 1998;56:1139–1144.
  31. Csonka C, Szilvassy Z, Pali T, Blasig IE, Tosaki A, Schulz R, Ferdinandy P: Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation 1999;100:2260–2266.
  32. Mülsch A, Mordvintcev P, Vanin A: Quantification of nitric oxide in biological samples by electron spin resonance spectroscopy. Neuroprotein 1992;1:165–173.
  33. Xie YW, Wolin MS: Role of nitric oxide and its interaction with superoxide in the suppression of cardiac muscle mitochondrial respiration. Involvement in response to hypoxia/reoxygenation. Circulation 1996;94:2580–2586.
  34. van der Vliet A, Eiserich JP, O’Neill CA, Halliwell B, Cross CE: Tyrosine modification by reactive nitrogen species: A closer look. Arch Biochem Biophys 1995;329:341–349.

    External Resources

  35. Ferdinandy P, Daniel H, Ambrus I, Rothery RA, Schulz R: Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000;87:241–247.
  36. Yasmin W, Strynadka KD, Schulz R: Generation of peroxinitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 1997;33:422–432.
  37. Ferdinandy P, Panas D, Schulz R: Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol 1999;276:H1861–H1867.

    External Resources

  38. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H: Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998;95:675–680.
  39. Szabó C: DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Rad Biol Med 1996;21:855–869.
  40. Levy BI, Curmi P, Poitevin P, Safar ME: Modifications of the arterial mechanical properties of normotensive and hypertensive rats without arterial pressure changes. J Cardiovasc Pharmacol 1989;14:253–259.

    External Resources

  41. Szilvassy Z, Koltai M, Szekeres L, Tarrade T, Braquet P: Effect of cicletanine on overpacing-induced ST-segment elevation in conscious rabbits. Eur J Pharmacol 1991;199:383–386.
  42. Szilvassy Z, Jakab I, Ferdinandy P, Koltai M, Lonovics J, Tarrade T, Braquet PG: Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits. Life Sci 1993;53:PL13–PL18.
  43. Ando K, Ono A, Sato Y, Asano S, Fujita T: Involvement of the sympathetic nervous system in antihypertensive effect of cicletanine in salt-loaded young spontaneously hypertensive rats. Am J Hypertens 1994;7:550–554.
  44. Jin H, Yang R-H, Oparil S: Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats. Am J Med Sci 1992;304:14–19.
  45. Flavahan NA: Atherosclerosis or lipoprotein-induced endothelial dysfunction: Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992;85:1927–1938.
  46. Taddei S, Virdis A, Ghiadoni L, Salvetti A: The role of endothelium in human hypertension. Current Opin Nephrol Hypertens 1998;7:203–209.
  47. Mugge A, Brandes RP, Boger RH, Dwenger A, Bode-Boger S, Kienke S, Frolich JC, Lichtlen PR: Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994;24:994–998.
  48. Miller FJJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL: Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998;82:1298–1305.

    External Resources

  49. Moriel P, Abdalla DS: Nitrotyrosine bound to beta-VLDL-apoproteins: A biomarker of peroxynitrite formation in experimental atherosclerosis. Biochem Biophys Res Commun 1997;232:332–335.

    External Resources

  50. Szabó C: The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 1996;6:79–88.
  51. Ma XL, Lopez BL, Liu GL, Christopher TA, Gao F, Guo Y, Feuerstein GZ, Ruffolo RRJ, Barone FC, Yue TL: Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997;80:894–901.

  

Author Contacts

Dr. Péter Ferdinandy, Associate Professor
Cardiovascular Research Group, Department of Biochemistry
University of Szeged, Dóm tér 9, H–6720 Szeged (Hungary)
Tel. +36 62 545096, Fax +36 62 455097
E-Mail peter@biochem.szote.u-szeged-hu, http://www.cardiovasc.com/

  

Article Information

Received: Received: April 14, 1999
Accepted after revision: August 15, 2000
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 1, Number of References : 51

  

Publication Details

Journal of Vascular Research
Founded 1964 as Angiologica by M. Comèl and L. Laszt (1964–1973) continued as Blood Vessels by J.A. Bevan (1974–1991)

Vol. 38, No. 1, Year 2001 (Cover Date: January-February 2001)

Journal Editor: M.J. Mulvany, Aarhus
ISSN: 1018–1172 (print), 1423–0135 (Online)

For additional information: http://www.karger.com/journals/jvr


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

We studied the effect of the furopyridine derivative antihypertensive drug, cicletanine, on blood pressure, vascular nitric oxide (NO) and cyclic guanosine 3′:5′-monophosphate (cGMP) content in the aorta and the renal and carotid arteries, aortic superoxide production, and serum nitrotyrosine level in hypertensive/atherosclerotic rabbits. The effect of cicletanine was compared to that of furosemide. Rabbits were fed a normal or a cholesterol-enriched (1.5%) diet over 8 weeks. On the 8th week, the rabbits were treated per os with 2 × 50 mg/kg daily doses of cicletanine, furosemide, or vehicle for 5 days (n = 5–6 in each groups). The cholesterol diet increased mean arterial blood pressure (MABP) from 86 ± 1 to 94 ± 2 mm Hg (p < 0.05). Cicletanine decreased MABP in atherosclerotic rabbits to 85 ± 1 mm Hg (p < 0.05), but it did not affect MABP in normal animals. Furosemide was without effect in both groups. In normal animals, NO content (assessed by electron spin resonance after in vivo spin trapping) in the aorta and the renal and carotid arteries was increased by cicletanine, and the drug increased cGMP in the renal artery as measured by radioimmunoassay. The cholesterol-enriched diet decreased both vascular NO and cGMP and increased aortic superoxide production assessed by lucigenin-enhanced chemiluminescence and serum nitrotyrosine determined by ELISA. In atherosclerotic animals, cicletanine increased NO and cGMP content in the aorta and the renal and carotid arteries and decreased aortic superoxide production and serum nitrotyrosine. Furosemide did not influence these parameters. We conclude that cicletanine lowers blood pressure in hypertensive/atherosclerotic rabbits. The antihypertensive effect of the drug in atherosclerosis may be based on its beneficial effects on the vascular NO-cGMP system and on the formation of reactive oxygen species.

© 2001 S. Karger AG, Basel


  

Author Contacts

Dr. Péter Ferdinandy, Associate Professor
Cardiovascular Research Group, Department of Biochemistry
University of Szeged, Dóm tér 9, H–6720 Szeged (Hungary)
Tel. +36 62 545096, Fax +36 62 455097
E-Mail peter@biochem.szote.u-szeged-hu, http://www.cardiovasc.com/

  

Article Information

Received: Received: April 14, 1999
Accepted after revision: August 15, 2000
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 1, Number of References : 51

  

Publication Details

Journal of Vascular Research
Founded 1964 as Angiologica by M. Comèl and L. Laszt (1964–1973) continued as Blood Vessels by J.A. Bevan (1974–1991)

Vol. 38, No. 1, Year 2001 (Cover Date: January-February 2001)

Journal Editor: M.J. Mulvany, Aarhus
ISSN: 1018–1172 (print), 1423–0135 (Online)

For additional information: http://www.karger.com/journals/jvr


Article / Publication Details

First-Page Preview
Abstract of Research Paper

Published online: 2/8/2001
Issue release date: January–February 2001

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1

ISSN: 1018-1172 (Print)
eISSN: 1423-0135 (Online)

For additional information: http://www.karger.com/JVR


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Chabrier PE, Guinot P, Tarrade T, et al: Cicletanine; in Scriabine A (ed): Cardiovascular Drug Reviews. New York, Raven Press, 1988;166–179.
  2. Bukowski RD, Wagman P, De Wan P, Xue H: Vascular actions of cicletanine. Arch Mal Coeur 1989;82:45–50.
  3. Silver PJ, O’Connor B, Cumiskey WR, Van Aller G, Hamel LT, Bentley RG, Pagani ED: Inhibition of low-Km cGMP phosphodiesterases and Ca++-regulated protein kinases and relationship to vasorelaxation by cicletanine. J Pharmacol Exp Ther 1991;257:382–391.

    External Resources

  4. Silver PJ, Buchholz A, Dundore RL, Harris AL, Pagani ED: Inhibition of low Km cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine. J Cardiovasc Pharmacol 1990;16:501–505.
  5. Szilvassy Z, Jakab I, Bor P, Koltai M, Tarrade T, Esanu A, Braquet PG, Lonovics J: Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: Possible role of cardiac cyclic nucleotides. Coronary Artery Dis 1993;4:443–452.
  6. Sakuta H, Okamoto K, Tandai M: Atrial natriuretic factor potentiates glibenclamide-sensitive K+ currents via activation of receptor guanylate cyclase in follicle-enclosed Xenopus oocytes. Eur J Pharmacol 1994;267:281–287.
  7. Yao XQ, Segal AS, Welling P, Zhang XQ, McNicholas CM, Engel D, Boulpaep EL, Desir GV: Primary structure and functional expression of a cGMP-gated potassium channel. Proc Natl Acad Sci USA 1995;92:11711–11715.

    External Resources

  8. Garay RP, Nazaret C, Diez J, Etienne A, Bourgain R, Braquet P: Stimulation of K+ fluxes by diuretic drugs in human red cells. Biochem Pharmacol 1984;33:2013–2020.
  9. Ebeigbe AB, Cabanie M: In vitro vascular effects of cicletanine in pregnancy-induced hypertension. Br J Pharmacol 1991;103:1992–1996.
  10. Ferdinandy P, Szilvassy Z, Droy-Lefaix MT, Tarrade T, Koltai M: KATP channel modulation in working rat hearts with coronary occlusion: Effects of cromakalim, cicletanine, and glibenclamide. Cardiovasc Res 1995;30:781–787.
  11. Najibi S, Cowan CL, Palacino JJ, Cohen RA: Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol 1994;266:H2061–H2067.

    External Resources

  12. Faraci FM, Heistad DD: Regulation of the cerebral circulation: Role of endothelium and potassium channels. Physiol Rev 1998;78:53–97.
  13. Bukoswki RD, Bo J, Xue H, Bian K: Antiproliferative and endothelium-dependent vasodilator properties of 1,3-dihydro-3-p-chlorophenyl-7-hydroxy-6-methyl-furo-(3,4c)pyridine hydrochloride (cicletanine). J Pharmacol Exp Ther 1993;265:30–35.
  14. Ferdinandy P, Szilvassy Z, Garay RP, Droy-Lefaix M-T: Interaction between vascular nitrate tolerance and cGMP phosphodiesterase inhibitors, cicletanine and zaprinast (abstract). J Mol Cell Cardiol 1999;30:A118.
  15. Dusting GJ: Nitric oxide in cardiovascular disorders. J Vasc Res 1995;32:143–161.
  16. Quyyumi AA: Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am J Med 1998;105:32S–39S.

    External Resources

  17. Ferdinandy P, Szilvassy Z, Baxter GF: Adaptation to myocardial stress in disease states: Is preconditioning a healthy heart phenomenon? Trends Pharmacol Sci 1998;19:223–229.
  18. Simonet S, Porro de Bailliencourt J, Descombes JJ, Mennecier P, Laubie M, Verbeuren TJ: Hypoxia causes an abnormal contractile response in the atherosclerotic rabbit aorta. Implication of reduced nitric oxide and cGMP production. Circ Res 1993;72:616–630.
  19. Lefer AM, Ma X: Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arteriosc Thromb 1993;13:771–776.
  20. Deliconstatinos G, Villioyou V, Stavrides JC: Modulation of particulate nitric oxide synthase activity and peroxynitrite synthesis in cholesterol enriched endothelial cell membranes. Biochem Pharmacol 1995;49:1589–1600.
  21. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E, Szentgyörgyi R, Nagy I, Koltai M, Dux L: Loss of pacing-induced preconditioning in rat hearts: Role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol 1997;29:3321–3333.
  22. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA, Tarpey MM: Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044–1048.
  23. Kojda G, Harrison D: Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999;43:562–571.
  24. McHugh J, Cheek DJ: Nitric oxide and regulation of vascular tone: Pharmacological and physiological considerations. Am J Crit Care 1998;7:131–140.
  25. Luscher TF, Noll G: Endothelial function as an end-point in interventional trials: Concepts, methods and current data. J Hypertens 1996;14:S111–S119.
  26. Szilvassy Z, Ferdinandy P, Bor P, Jakab I, Lonovics J, Koltai M: Ventricular overdrive pacing-induced anti-ischemic effect: A conscious rabbit model of preconditioning. Am J Physiol 1994;266:H2033–H2041.

    External Resources

  27. Szilvassy Z, Ferdinandy P, Szilvassy J, Nagy I, Karcsu S, Lonovics J, Dux L, Koltai M: The loss of pacing-induced preconditioning in atherosclerotic rabbits: Role of hypercholesterolemia. J Mol Cell Cardiol 1995;27:2559–2569.
  28. Szilvassy Z, Ferdinandy P, Cluff CW, Elliott GT: Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis. J Cardiovasc Pharmacol 1998;32:206–212.
  29. Ferdinandy P, Csont T, Csonka C, Torok M, Dux M, Nemeth J, Horvath LI, Dux L, Szilvassy Z, Jancso G: Capsaicin-sensitive local sensory innervation is involved in pacing-induced preconditioning in rat hearts: Role of nitric oxide and CGRP? Naunyn Schmiedebergs Arch Pharmacol 1997;356:356–363.
  30. Csont T, Pali T, Szilvassy Z, Ferdinandy P: Lack of correlation between myocardial nitric oxide and cyclic guanosine monophosphate content in both nitrate-tolerant and nontolerant rats. Biochem Pharmacol 1998;56:1139–1144.
  31. Csonka C, Szilvassy Z, Pali T, Blasig IE, Tosaki A, Schulz R, Ferdinandy P: Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation 1999;100:2260–2266.
  32. Mülsch A, Mordvintcev P, Vanin A: Quantification of nitric oxide in biological samples by electron spin resonance spectroscopy. Neuroprotein 1992;1:165–173.
  33. Xie YW, Wolin MS: Role of nitric oxide and its interaction with superoxide in the suppression of cardiac muscle mitochondrial respiration. Involvement in response to hypoxia/reoxygenation. Circulation 1996;94:2580–2586.
  34. van der Vliet A, Eiserich JP, O’Neill CA, Halliwell B, Cross CE: Tyrosine modification by reactive nitrogen species: A closer look. Arch Biochem Biophys 1995;329:341–349.

    External Resources

  35. Ferdinandy P, Daniel H, Ambrus I, Rothery RA, Schulz R: Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000;87:241–247.
  36. Yasmin W, Strynadka KD, Schulz R: Generation of peroxinitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 1997;33:422–432.
  37. Ferdinandy P, Panas D, Schulz R: Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol 1999;276:H1861–H1867.

    External Resources

  38. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H: Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998;95:675–680.
  39. Szabó C: DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Rad Biol Med 1996;21:855–869.
  40. Levy BI, Curmi P, Poitevin P, Safar ME: Modifications of the arterial mechanical properties of normotensive and hypertensive rats without arterial pressure changes. J Cardiovasc Pharmacol 1989;14:253–259.

    External Resources

  41. Szilvassy Z, Koltai M, Szekeres L, Tarrade T, Braquet P: Effect of cicletanine on overpacing-induced ST-segment elevation in conscious rabbits. Eur J Pharmacol 1991;199:383–386.
  42. Szilvassy Z, Jakab I, Ferdinandy P, Koltai M, Lonovics J, Tarrade T, Braquet PG: Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits. Life Sci 1993;53:PL13–PL18.
  43. Ando K, Ono A, Sato Y, Asano S, Fujita T: Involvement of the sympathetic nervous system in antihypertensive effect of cicletanine in salt-loaded young spontaneously hypertensive rats. Am J Hypertens 1994;7:550–554.
  44. Jin H, Yang R-H, Oparil S: Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats. Am J Med Sci 1992;304:14–19.
  45. Flavahan NA: Atherosclerosis or lipoprotein-induced endothelial dysfunction: Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992;85:1927–1938.
  46. Taddei S, Virdis A, Ghiadoni L, Salvetti A: The role of endothelium in human hypertension. Current Opin Nephrol Hypertens 1998;7:203–209.
  47. Mugge A, Brandes RP, Boger RH, Dwenger A, Bode-Boger S, Kienke S, Frolich JC, Lichtlen PR: Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994;24:994–998.
  48. Miller FJJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL: Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998;82:1298–1305.

    External Resources

  49. Moriel P, Abdalla DS: Nitrotyrosine bound to beta-VLDL-apoproteins: A biomarker of peroxynitrite formation in experimental atherosclerosis. Biochem Biophys Res Commun 1997;232:332–335.

    External Resources

  50. Szabó C: The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 1996;6:79–88.
  51. Ma XL, Lopez BL, Liu GL, Christopher TA, Gao F, Guo Y, Feuerstein GZ, Ruffolo RRJ, Barone FC, Yue TL: Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997;80:894–901.